Pivotal studies show average 1-2 pound loss by week 2, 4-6 pounds by week 4 with consistent dosing
3,4 Moreover, experiments involving drug-resistant cell lines have also demonstrated increased GST expression
For personalized guidance, consult your healthcare provider, registered dietitian nutritionist (RD or RDN), or pharmacist
In other words, subjects will likely need a higher dose of intranasal spray to achieve comparable results to injections
Retatrutide leads on published weight loss data (28.3% vs ~19% survodutide and 20.9% tirzepatide), receptor coverage (triple agonist vs dual), and liver fat reduction (82%)
Key findings: STEP 1 (68 weeks, 2.4 mg Wegovy, n=1,961): 44% of participants reported nausea, with the majority resolving it within the dose-escalation phase